| dc.description.abstract | Background: Papillary thyroid carcinoma (PTC) is an indolent thyroid malignancy with clinicopathological features that play a role in prognosis. BRAFV600E mutations in PTC have a poor prognosis and BRAFV600E immunohistochemical staining shows high levels of specificity and sensitivity.
Objective: Knowing the immunohistochemical expression BRAFV600E on PTC and analyzed based on clinical features and histopathological subtypes.
Materials and Methods: This research method is an analytical study with a cross-sectional approach, the number of samples is 35 PTC patients diagnosed by hematoxylin-eosin (H&E) at the Anatomical Pathology Laboratory, Faculty of Medicine, Universitas Sumatera Utara and the Anatomical Pathology Unit of Prof. Dr. Chairuddin Panusunan Lubis Teaching Hospital, Medan. Clinical data in the form of secondary data from medical records that meet the inclusion criteria, a histopathological diagnosis review was carried out and continued with BRAFV600E immunohistochemical staining.(Clone IHC 600 Gene Ab™ Monoclonal Mouse Anti-Human, GenomeMe, dilution 1:30). Analyzed data by testing Somers'd and Eta, the assessment results are presented in tabular form.
Results: In this study, PTC was most common in the age group <45 years, in women, the most tumor size was >4 cm (T3), without lymph node involvement (N0) and without metastasis (M0). The most common PTC histopathology was the classic sub-type, without lymphovascular invasion (LVI) and in stage I. Analysis of the relationship between BRAFV600E expression with clinicopathology (test) Somers'd and Eta), there was no significant relationship (p > 0.05), but for stage there was a significant relationship (p < 0.05).
Conclusion: There is noconnection meaning between expressions BRAFV600E immunohistochemistry with clinicopathology based on age, gender, tumor size, lymph nodes, metastasis, LVI and histopathological sub-type of PTC, but there is a relationship with stage in PTC. | en_US |
